1st Order acquired 1OP2198 from an undisclosed third party, and Xenon will have to honor financial responsibilities under that deal. The firm expects to make up-front and milestone payments of $1.1 million in 2017. Moving forward, payments due to 1st Order and the third party could include $1 million in clinical development milestones, up to $13 million in regulatory milestones, and up to about $33.6 million in sales-based and other milestones, plus sales royalties.
Read Full Story Here
